ZA200110004B - Use of antibodies against CD20 for the treatment of the graft versus host disease. - Google Patents

Use of antibodies against CD20 for the treatment of the graft versus host disease.

Info

Publication number
ZA200110004B
ZA200110004B ZA200110004A ZA200110004A ZA200110004B ZA 200110004 B ZA200110004 B ZA 200110004B ZA 200110004 A ZA200110004 A ZA 200110004A ZA 200110004 A ZA200110004 A ZA 200110004A ZA 200110004 B ZA200110004 B ZA 200110004B
Authority
ZA
South Africa
Prior art keywords
treatment
antibodies against
host disease
versus host
graft versus
Prior art date
Application number
ZA200110004A
Other languages
English (en)
Inventor
Josee Golay
Martino Introna
Alessandro Rambaldi
Andrea Biondi
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Publication of ZA200110004B publication Critical patent/ZA200110004B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA200110004A 1999-06-11 2001-12-05 Use of antibodies against CD20 for the treatment of the graft versus host disease. ZA200110004B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite

Publications (1)

Publication Number Publication Date
ZA200110004B true ZA200110004B (en) 2003-02-26

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110004A ZA200110004B (en) 1999-06-11 2001-12-05 Use of antibodies against CD20 for the treatment of the graft versus host disease.

Country Status (26)

Country Link
US (1) US20070014785A1 (da)
EP (1) EP1185299B1 (da)
JP (1) JP2003501482A (da)
KR (1) KR20020026455A (da)
CN (1) CN1253208C (da)
AU (1) AU774206B2 (da)
BG (1) BG106193A (da)
CA (1) CA2376288A1 (da)
CZ (1) CZ20014450A3 (da)
DE (1) DE60033030T2 (da)
DK (1) DK1185299T3 (da)
EE (1) EE200100667A (da)
ES (1) ES2278616T3 (da)
HK (1) HK1043549B (da)
HU (1) HUP0201600A3 (da)
IL (1) IL146934A0 (da)
IS (1) IS6195A (da)
IT (1) ITMI991299A1 (da)
NO (1) NO20016035L (da)
NZ (1) NZ515992A (da)
PL (1) PL352860A1 (da)
PT (1) PT1185299E (da)
SK (1) SK18132001A3 (da)
TR (1) TR200103581T2 (da)
WO (1) WO2000076542A1 (da)
ZA (1) ZA200110004B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP2289936B1 (en) * 2002-12-16 2017-05-31 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
US20050095243A1 (en) 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
CA2560751A1 (en) * 2004-03-22 2005-10-06 The Ohio State University Research Foundation Methods for transfecting natural killer cells
MXPA06014069A (es) 2004-06-04 2007-04-25 Genentech Inc Metodo para tratar esclerosis multiple.
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
RU2421242C2 (ru) 2005-07-25 2011-06-20 Трабьон Фармасьютикалз, Инк. Применение однократной дозы cd20-специфических связывающих молекул
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
US20100183586A1 (en) * 2007-06-22 2010-07-22 Tsukasa Hori Method for detection or treatment of graft versus host disease
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101809037B (zh) 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017006312A (es) 2014-11-17 2017-08-21 Regeneron Pharma Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
CA2984635A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AU2016326449B2 (en) 2015-09-21 2024-10-31 Aptevo Research And Development Llc CD3 binding polypeptides
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
MX2021002190A (es) 2018-08-31 2021-05-14 Regeneron Pharma Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0977595A4 (en) * 1996-05-31 2001-05-16 Genetic Therapy Inc PREVENTION OF GAS REACTION AGAINST HOST USING THYMO-DEPENDENT LYMPHOCYTES CONTAINING POLYNUCLEOTIDES ENCODING NEGATIVE SELECTION MARKERS
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
ITMI991299A0 (it) 1999-06-11
CA2376288A1 (en) 2000-12-21
TR200103581T2 (tr) 2002-08-21
NZ515992A (en) 2004-01-30
HK1043549A1 (en) 2002-09-20
SK18132001A3 (sk) 2002-05-09
AU774206B2 (en) 2004-06-17
ES2278616T3 (es) 2007-08-16
CN1355712A (zh) 2002-06-26
NO20016035D0 (no) 2001-12-10
KR20020026455A (ko) 2002-04-10
DE60033030T2 (de) 2007-05-31
DK1185299T3 (da) 2007-05-21
NO20016035L (no) 2002-02-11
US20070014785A1 (en) 2007-01-18
EP1185299A1 (en) 2002-03-13
HUP0201600A3 (en) 2005-04-28
BG106193A (bg) 2002-08-30
ITMI991299A1 (it) 2000-12-11
HUP0201600A2 (en) 2002-08-28
AU5530300A (en) 2001-01-02
DE60033030D1 (de) 2007-03-08
WO2000076542A1 (en) 2000-12-21
PT1185299E (pt) 2007-03-30
HK1043549B (zh) 2006-09-01
IL146934A0 (en) 2002-08-14
EE200100667A (et) 2003-02-17
JP2003501482A (ja) 2003-01-14
CN1253208C (zh) 2006-04-26
IS6195A (is) 2001-12-10
CZ20014450A3 (cs) 2002-04-17
EP1185299B1 (en) 2007-01-17
PL352860A1 (en) 2003-09-08

Similar Documents

Publication Publication Date Title
ZA200110004B (en) Use of antibodies against CD20 for the treatment of the graft versus host disease.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
ZA99452B (en) Antibodies against human IL-12.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
EP1575491A4 (en) TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
ZA200108905B (en) Use of macrolide compounds for the treatment of dry eye.
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
ZA200003236B (en) Combination therapy for the treatment of migraine.
AU5497000A (en) Non-malignant disease treatment with ras antagonists
MXPA02004942A (es) Nuevo uso de anticuerpos como vacunas.
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200105690B (en) Novel treatment.
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AP2004003070A0 (en) The method of treating cancer.
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
ZA200202841B (en) Apparatus for treating fluids.
ZA200203166B (en) Treatment of cancer.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
SI1185299T1 (sl) Uporaba protiteles proti cd20 za zdravljenje reakcije presadka proti gostitelju